Skip to main content
. 2020 Dec 17;10:575739. doi: 10.3389/fonc.2020.575739

Table 1.

Summary of response to EGFR-TKIs in NSCLCs harboring EGFR-KDDs.

Study Population Best response to TKIs TKIs, response and PFS
Our case East Asian PR Icotinib, PR, 4m; Osimertinib, PR, 21m
Gallant et al. (1) American PR Afatinib, PR, 10m
Baik et al. (6) American PR Gefitinib, PR, 6y; Erlotinib, PR, 3y
Wiest et al. (7) Germany PR Afatinib, PR, NA
Zhu et al. (8) East Asian SD Icotinib, SD, 11m (Not reach)
Xu et al. (9) East Asian PR Afatinib, PR, NA
Wang et al. (3) East Asian SD Icotinib, SD, NA
Wang et al. (4) East Asian PD Erlotinib, PD, 2m; Osimertinib, PD, 2m
East Asian PR Gefitinib, PR, 5m; Afatinib, PD, 2m
Osimertinib, PR, 4m (Not reach)
East Asian SD Gefitinib, SD, 11m
East Asian PR Icotinib+apatinib, PR, 4m (Not reach)
East Asian PD Gefitinib, PD, 3m
Erlotinib, PD, 5m
HHS Vulnerability Disclosure